HCTI vs HIMS vs HCAT vs MTEX vs VEEV

For growth investors, Hims & Hers Health, Inc.

(HIMS) is the stronger pick with 59. 0% revenue growth year-over-year, versus -64. 8% for Healthcare Triangle, Inc. (HCTI). Mannatech, Incorporated (MTEX) offers the better valuation at 3. 5x trailing P/E, making it the more compelling value choice. Analysts rate Health Catalyst, Inc. (HCAT) a "Buy" — based on 22 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Mannatech, Incorporated (MTEX) is the cheapest at 3.

5x versus Hims & Hers Health, Inc. at 50. 3x. On forward P/E, Health Catalyst, Inc. is actually cheaper at 14. 1x — notably different from the trailing picture, reflecting expected earnings growth.

Over the past 5 years, Hims & Hers Health, Inc.

(HIMS) delivered a total return of +137. 6%, compared to -100. 0% for Healthcare Triangle, Inc. (HCTI). Over 10 years, the gap is even starker: VEEV returned +519. 4% versus HCTI's -100. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Mannatech, Incorporated (MTEX) is the lower-risk stock at 0.

27β versus Healthcare Triangle, Inc. 's 3. 07β — meaning HCTI is approximately 1047% more volatile than MTEX relative to the S&P 500. On balance sheet safety, Veeva Systems Inc. (VEEV) carries a lower debt/equity ratio of 1% versus 2% for Hims & Hers Health, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Hims & Hers Health, Inc.

(HIMS) is pulling ahead at 59. 0% versus -64. 8% for Healthcare Triangle, Inc. (HCTI). On earnings-per-share growth, the picture is similar: Mannatech, Incorporated grew EPS 210. 0% year-over-year, compared to -121. 7% for Health Catalyst, Inc.. Over a 3-year CAGR, HIMS leads at 64. 5% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Veeva Systems Inc.

(VEEV) is the more profitable company, earning 28. 4% net margin versus -57. 2% for Health Catalyst, Inc. — meaning it keeps 28. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: VEEV leads at 28. 7% versus -51. 7% for HCAT. At the gross margin level — before operating expenses — MTEX leads at 77. 6%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Health Catalyst, Inc.

(HCAT) trades at 14. 1x forward P/E versus 51. 5x for Hims & Hers Health, Inc. — 37. 4x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for VEEV: 66. 5% to $280. 10.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Mannatech, Incorporated (MTEX) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

27)). Healthcare Triangle, Inc. (HCTI) carries a higher beta of 3. 07 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (MTEX: -35. 2%, HCTI: -100. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (HCTI (Healthcare) and HIMS (Healthcare) and HCAT (Healthcare) and MTEX (Consumer Defensive) and VEEV (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: HCTI is a small-cap quality compounder stock; HIMS is a small-cap high-growth stock; HCAT is a small-cap quality compounder stock; MTEX is a small-cap deep-value stock; VEEV is a mid-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.